Results 111 to 120 of about 1,054 (155)

Gepants for headache prevention in children and adolescents: A multicenter chart review study. [PDF]

Headache
Shin L, Mentz O, Gelfand AA, de Prado BM, Shapiro H, Oh A, Onifade OO, Saunders J, Raj N, Szperka CL.   +9 more
europepmc   +1 more source

Patient-reported outcomes of rimegepant for acute and preventive treatment of migraine in China: a prospective, multicenter, real-world study. [PDF]

J Headache Pain
Wang J, Jiang J, Peng S, Jiang J, Liu Z, Cai J, Li J, Li Y, Chen Y, Li H, Rong X, He L, Ren L, Ji Y, Li S, Zhu Y, Xiao S, Tang Y, Xu Y.   +18 more
europepmc   +1 more source

An integrated multimodal approach to drug repurposing in endometriosis, using ROR1 as a target. [PDF]

Front Pharmacol
Gunther K, Liu D, Stannard G, Holmes M, Loo C, Guo B, Bowden N, Abbott J, Ford CE.   +8 more
europepmc   +1 more source

Innovations in conservative and surgical therapy for Ménière's disease-narrative review. [PDF]

Front Neurol
Jasińska-Nowacka A, Zienkiewicz D, Makuszewska M, Wojciechowski T, Kaczmarczyk M, Niemczyk K.   +5 more
europepmc   +1 more source

The influence of renal impairment on the pharmacokinetics of rimegepant: Results of a phase 1, open-label, single-dose, parallel-group study. [PDF]

Headache
Bhardwaj R, Morris B, Bertz R, Matschke K, Croop R, Liu J.   +5 more
europepmc   +1 more source

Evaluating Rimegepant for the Treatment of Migraine [PDF]

Expert Opinion on Pharmacotherapy, 2021
IntroductionCalcitonin gene-related peptide (CGRP) is a vasodilatory neuropeptide involved in the pathophysiology of migraine, a highly disabling neurovascular disorder characterized by severe headache attacks. Rimegepant is a small-molecule CGRP receptor antagonist approved by the FDA for acute treatment of migraine and currently under investigation ...
Antoinette MaassenVanDenBrink
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Rimegepant Oral Disintegrating Tablet for Migraine

Lancet, The, 2019
Lars Edvinsson
exaly   +3 more sources

Rimegepant for the treatment of migraine

Drugs of Today, 2020
Rimegepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist developed with a novel quick-dissolve oral tablet formulation for the acute treatment of migraine by Biohaven Pharmaceuticals, under license from Bristol Myers Squibb. The completed phase II and III trials showed its efficacy in terms of pain freedom, pain relief, release ...
Negro A., Martelletti P.
openaire   +2 more sources

Rimegepant: Acute Treatment for Migraine Headaches

Pain Management, 2021
Migraine headache treatment is quickly evolving. There have been three new acute migraine treatment options (i.e., lasmiditan, rimegepant, ubrogepant) and four new preventive migraine treatment options (i.e., erenumab, fremanezumab, galcanezumab, eptinezumab) released in the past 3 years.
Golden L Peters, Erin K Hennessey
openaire   +2 more sources